Relationships with Patient Organisations
At Immunocore, we value collaboration and partnerships.
Our commitment to working with patient organisations for the benefit of patients, is in accordance with the requirements of Clause 27 of the ABPI Code of Practice for the Pharmaceutical Industry.
Immunocore upholds the highest standards of integrity in the way that we conduct business and we fully support the industry movement toward increased transparency of financial relationships. Disclosure of our financial support to patient organisations is one of the activities that we undertake to improve transparency concerning Company dealings with third parties.
Immunocore declares that the Company has made its best efforts to make a comprehensive disclosure of concerned activities for 2024 and from hereon in.